202 related articles for article (PubMed ID: 34764021)
1. Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety net.
Sommerburg O; Stahl M; Hämmerling S; Gramer G; Muckenthaler MU; Okun J; Kohlmüller D; Happich M; Kulozik AE; Mall MA; Hoffmann GF
J Cyst Fibros; 2022 May; 21(3):422-433. PubMed ID: 34764021
[TBL] [Abstract][Full Text] [Related]
2. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
[TBL] [Abstract][Full Text] [Related]
3. Five years of experience with biochemical cystic fibrosis newborn screening based on IRT/PAP in Germany.
Sommerburg O; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Stopsack M; Gahr M; Hoffmann GF; Mall MA
Pediatr Pulmonol; 2015 Jul; 50(7):655-64. PubMed ID: 25914230
[TBL] [Abstract][Full Text] [Related]
4. Comparison of different IRT-PAP protocols to screen newborns for cystic fibrosis in three central European populations.
Sommerburg O; Krulisova V; Hammermann J; Lindner M; Stahl M; Muckenthaler M; Kohlmueller D; Happich M; Kulozik AE; Votava F; Balascakova M; Skalicka V; Stopsack M; Gahr M; Macek M; Mall MA; Hoffmann GF
J Cyst Fibros; 2014 Jan; 13(1):15-23. PubMed ID: 23891278
[TBL] [Abstract][Full Text] [Related]
5. Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
Krulišová V; Balaščaková M; Skalická V; Piskáčková T; Holubová A; Paděrová J; Křenková P; Dvořáková L; Zemková D; Kračmar P; Chovancová B; Vávrová V; Stambergová A; Votava F; Macek M
Eur J Pediatr; 2012 Aug; 171(8):1223-9. PubMed ID: 22581207
[TBL] [Abstract][Full Text] [Related]
6. Optimization of performance of Dutch newborn screening for cystic fibrosis.
Bouva MJ; Dankert-Roelse JE; van der Ploeg C; Verschoof-Puite RK; Zomer-van Ommen DD; Gille J; Jakobs BS; Heijnen M; de Winter-de Groot KM
J Cyst Fibros; 2024 Jan; 23(1):120-125. PubMed ID: 37716879
[TBL] [Abstract][Full Text] [Related]
7. A model-based economic evaluation of four newborn screening strategies for cystic fibrosis in Flanders, Belgium.
Schmidt M; Werbrouck A; Verhaeghe N; De Wachter E; Simoens S; Annemans L; Putman K
Acta Clin Belg; 2020 Jun; 75(3):212-220. PubMed ID: 31007159
[No Abstract] [Full Text] [Related]
8. Cost effectiveness of newborn screening for cystic fibrosis: a simulation study.
Nshimyumukiza L; Bois A; Daigneault P; Lands L; Laberge AM; Fournier D; Duplantie J; Giguère Y; Gekas J; Gagné C; Rousseau F; Reinharz D
J Cyst Fibros; 2014 May; 13(3):267-74. PubMed ID: 24238947
[TBL] [Abstract][Full Text] [Related]
9. Diagnosing cystic fibrosis in newborn screening in Poland - 15 years of experience.
Sands D; Zybert K; Mierzejewska E; Ołtarzewski M
Dev Period Med; 2015; 19(1):16-24. PubMed ID: 26003066
[TBL] [Abstract][Full Text] [Related]
10. [Newborn Screening on Cystic Fibrosis in Germany: Comparison of the new Screening Protocol with an Alternative Protocol].
Sommerburg O; Stahl M; Hammermann J; Okun JG; Kulozik A; Hoffmann G; Mall M
Klin Padiatr; 2017 Mar; 229(2):59-66. PubMed ID: 28444650
[No Abstract] [Full Text] [Related]
11. A product of immunoreactive trypsinogen and pancreatitis-associated protein as second-tier strategy in cystic fibrosis newborn screening.
Weidler S; Stopsack KH; Hammermann J; Sommerburg O; Mall MA; Hoffmann GF; Kohlmüller D; Okun JG; Macek M; Votava F; Krulišová V; Balaščaková M; Skalická V; Lee-Kirsch MA; Stopsack M
J Cyst Fibros; 2016 Nov; 15(6):752-758. PubMed ID: 27461140
[TBL] [Abstract][Full Text] [Related]
12. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
13. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
14. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of specificity and sensitivity of IRT/IRT protocol in the cystic fibrosis newborn screening program: 6-year experience of three tertiary centers.
Ramasli Gursoy T; Asfuroglu P; Sismanlar Eyuboglu T; Aslan AT; Yilmaz AI; Unal G; Kibar BS; Pekcan S; Hangul M; Kose M; Budakoglu II; Acican D
Eur J Pediatr; 2023 Mar; 182(3):1067-1076. PubMed ID: 36565324
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactive trypsinogen in healthy newborns and infants with cystic fibrosis.
Fingerhut R; Rueegg CS; Imahorn O; Pedersen ESL; Kuehni CE; Gallati S; Regamey N; Barben J
Arch Dis Child Fetal Neonatal Ed; 2023 Mar; 108(2):176-181. PubMed ID: 36351789
[TBL] [Abstract][Full Text] [Related]
17. Comparison between two newborn screening strategies for cystic fibrosis in Argentina: IRT/IRT versus IRT/PAP.
Teper A; Smithuis F; Rodríguez V; Salvaggio O; Maccallini G; Aranda C; Lubovich S; Zaragoza S; García-Bournissen F
Pediatr Pulmonol; 2021 Jan; 56(1):113-119. PubMed ID: 33095477
[TBL] [Abstract][Full Text] [Related]
18. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
19. PAP assays in newborn screening for cystic fibrosis: a population-based cost-effectiveness study.
Seror V; Cao C; Roussey M; Giorgi R
J Med Screen; 2016 Jun; 23(2):62-9. PubMed ID: 26304152
[TBL] [Abstract][Full Text] [Related]
20. Impact of Pancreatitis-Associated Protein on Newborn Screening Outcomes and Detection of CFTR-Related Metabolic Syndrome (CRMS)/Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): A Monocentric Prospective Pilot Experience.
Bianchimani C; Dolce D; Centrone C; Campana S; Ravenni N; Orioli T; Camera E; Mergni G; Fevola C; Bonomi P; Taccetti G; Terlizzi V
Int J Neonatal Screen; 2022 Aug; 8(3):. PubMed ID: 35997436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
